Testing is performed on Abbott’s ID NOW platform. Credit: Abbott.

Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates

Follow the latest updates of the outbreak on our timeline.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The US Food and Drug Administration (FDA) has granted emergency use authorisation (EUA) for Abbott’s new molecular point-of-care test to detect coronavirus (Covid-19).

The latest test runs on the company’s ID NOW platform and delivers positive results in five minutes and negative results within 13 minutes.

The ID NOW platform is a rapid, instrument-based, isothermal system used for the qualitative detection of infectious diseases.

Its isothermal nucleic acid amplification technology enables molecular results in minutes. Furthermore, it is small, lightweight and portable.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Abbott president and chief CEO Robert Ford said: “The Covid-19 pandemic will be fought on multiple fronts and a portable molecular test that offers results in minutes adds to the broad range of diagnostic solutions needed to combat this virus.

“With rapid testing on ID NOW, healthcare providers can perform molecular point-of-care testing outside the traditional four walls of a hospital in outbreak hotspots.”

The company said it expects to scale up manufacturing to deliver 50,000 tests per day to meet the current demand for coronavirus tests. The ID NOW Covid-19 test will be launched next week.

It is the second EUA secured by Abbott for Covid-19 detection. The company received its first EUA for RealTime SARS-CoV-2 test from the US FDA this month.

RealTime SARS-CoV-2 is another molecular test for Covid-19 that runs on its m2000 RealTime System.

Combining both its Covid-19 tests, Abbott plans to deliver approximately five million tests per month to keep up with the diagnosis requirements.

Meanwhile, 143,025 confirmed coronavirus cases have been reported in the US. The death toll has reached over 2,509 in the country.

Medical Device Network Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Medical Device Network Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving medical devices advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now